Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2004-05-13
2008-07-01
Minnifield, Nita (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S420000, C424S450000, C424S184100, C424S234100, C424S278100, C424S280100, C424S093100, C424S093400, C435S243000, C435S253100
Reexamination Certificate
active
07393541
ABSTRACT:
Compositions and methods for enhancing the immunity of a subject or vaccinating a subject against mycobacterial infections are disclosed. The invention provides compositions comprising formalin inactivated cultures of a mycobacterium, such asM. bovis, and a Novasome® adjuvant, as well as methods for using such compositions.
REFERENCES:
patent: 5474848 (1995-12-01), Wallach
patent: 6290987 (2001-09-01), Modi
patent: 6387373 (2002-05-01), Wright et al.
patent: 6649172 (2003-11-01), Johnson
patent: 6936260 (2005-08-01), Schroder et al.
patent: 2004/0133160 (2004-07-01), Dalton
patent: 2005/0118201 (2005-06-01), Wright et al.
patent: 2005/0175630 (2005-08-01), Raz et al.
patent: WO 00/47225 (2000-08-01), None
patent: WO 03/051288 (2003-06-01), None
World Health Organization. Global Tuberculosis Control. WHO Reprot 2001. Geneva, Switzerland, WHO/CDS/TB/2001:287, pp. 1-34.
Orme, Microbes and Infection, 2005, 7:905-910.
Griffin et al, Trends in Microbiology, Nov. 1995, 3/11:418-424.
Andersen, Trends in Immunology, Mar. 2001, 22/3:160-168.
McMurray, International J. Parasitology, 2003, 33:547-554.
Smith et al, Clinical Infectious Diseases, 2000, 31(Suppl. 3):S68-S70.
Girard et al, Vaccine, 2005, Article in Press, 7 pp.
Orme, Vaccine, 2005, Article in Press, 18 pp.
Reed et al, Microbes and Infection, 2005, 7:922-931.
Orme, Vaccine, 2005, 23:2105-2108.
Lima et al, Vaccine, 2004, 22:2374-2379.
O'Hagan et al, Biomolecular Engineering, 2001, 18:69-85.
Chambers et al, Vaccine, 2004, 22:1063-1071.
Buddle, Tuberculosis, 2001, 81/1-2:125-132.
Guleria et al, Nature Medicine, 1996, 2/3:334-337.
Robertson et al, Vaccine, 2002, 20:31-41.
Andersen, Scand. J. Immunol., 1997, 45:115-131.
Bachmann et al, DDT, Jun. 2001, 6/11:566-568.
Wiegeshaus et al, Reviews Infectious Diseases, 1989, 11/Suppl. 2:S484-S490.
Vogel, Clinical Infectious Diseases, 2000, 30/Suppl. 3:S266-S270.
Vogel et al In: Vaccine Design: The Subunits and Adjuvant Approach, editors Powell et al, 1995, pp. 141, 186-187.
PCT International Preliminary Examination Report PCT/US02/36336, filed Nov. 13, 2002.
Griffin, J.F.T., et al., Animal models of protective immuni in tuberculosis to evaluate candidate vaccines. Trends in Microbiology, Nov. 1995, vol. 3, No. 11, pp. 418-424.
Smith, D., et al., Animal Models for Experimental Tuberculosis. Clinical Infectious Diseases. 2000, vol. 31, supplement 3, pp. S68-S70.
Wiegeshaus, E.H., et al., Evaluation of the Protective Potency of New Tuberculosis Vaccines. Reviews of Infectious Diseases. Mar. 1989, vol. 11, Supplement 2, pp. S484-S490.
International Search Report for International Application No. PCT/US02/36336.
Brisker Joan
Chambers Mark A.
Wright D. Craig
Edwards Angell Palmer & & Dodge LLP
Loren Ralph A.
Minnifield Nita
Novavax Inc.
LandOfFree
Mycobacterial vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mycobacterial vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mycobacterial vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3970274